Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001027333 | SCV001189873 | pathogenic | Hereditary cancer-predisposing syndrome | 2018-12-20 | criteria provided, single submitter | clinical testing | The p.W275* pathogenic mutation (also known as c.825G>A), located in coding exon 7 of the SUFU gene, results from a G to A substitution at nucleotide position 825. This changes the amino acid from a tryptophan to a stop codon within coding exon 7. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV001238662 | SCV001411487 | pathogenic | Gorlin syndrome; Medulloblastoma | 2021-01-28 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals with SUFU-related conditions. ClinVar contains an entry for this variant (Variation ID: 827539). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Trp275*) in the SUFU gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SUFU are known to be pathogenic (PMID: 22508808, 25403219). |